Literature DB >> 4339887

Monoamine oxidase in sympathetic nerves: a transmitter specific enzyme type.

C Goridis, N H Neff.   

Abstract

1. When rat brain or superior cervical ganglion monoamine oxidase was incubated with increasing concentrations of clorgyline, using tyramine as substrate, the inhibition of the enzyme could be represented by a pair of sigmoidal curves joined by a horizontal region where inhibition was constant. Tyramine appeared to be metabolized by two enzymes, one of which was highly sensitive to clorgyline, designated A, whereas the other enzyme, designated B, was less sensitive to clorgyline.2. The ratio of A/B activity for brain was 6/4 while in the ganglion it was 9/1.3. When the experiments were repeated using noradrenaline as the substrate, the inhibition of the enzyme followed a simple sigmoidal curve where deamination was inhibited by low concentrations of clorgyline as observed with enzyme A.4. We conclude that tyramine is deaminated by both A and B enzymes whereas noradrenaline is deaminated only by enzyme A, the enzyme which is most active in the ganglion. Our observations are consistent with the hypothesis that a specific intraneuronal monoamine oxidase plays an important role in the catabolism of noradrenaline in sympathetic nerves.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4339887      PMCID: PMC1665724          DOI: 10.1111/j.1476-5381.1971.tb07217.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Isoenzymes of human and rat liver monoamine oxidase.

Authors:  G G.S. Collins; M B.H. Youdim; M Sandler
Journal:  FEBS Lett       Date:  1968-09       Impact factor: 4.124

2.  The role of monoamine oxidase in the release and metabolism of norepinephrine.

Authors:  I J KOPIN; J AXELROD
Journal:  Ann N Y Acad Sci       Date:  1963-07-08       Impact factor: 5.691

3.  Formation of phenolic acids in brain after administration of 3,4-dihydroxyphenylalanine.

Authors:  A CARLSSON; N A HILLARP
Journal:  Acta Physiol Scand       Date:  1962-05

4.  Evidence for a specific monoamine oxidase associated with sympathetic nerves.

Authors:  C Goridis; N H Neff
Journal:  Neuropharmacology       Date:  1971-09       Impact factor: 5.250

5.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors:  J P Johnston
Journal:  Biochem Pharmacol       Date:  1968-07       Impact factor: 5.858

6.  Multiple monoamine oxidases in rat liver mitochondria.

Authors:  L Sierens; A D'Iorio
Journal:  Can J Biochem       Date:  1970-06

7.  Multiple forms of rat brain monoamine oxidase.

Authors:  M B Youdim; G G Collins; M Sandler
Journal:  Nature       Date:  1969-08-09       Impact factor: 49.962

8.  A sensitive and specific fluorescence assay for tissue serotonin.

Authors:  S H Snyder; J Axelrod; M Zweig
Journal:  Biochem Pharmacol       Date:  1965-05       Impact factor: 5.858

9.  Occurrence and properties of monoamine oxidase in adrenergic neurons.

Authors:  B Jarrott
Journal:  J Neurochem       Date:  1971-01       Impact factor: 5.372

10.  The physiologic disposition and metabolism of norepinephrine in immunosympathectomized animals.

Authors:  L L Iversen; J Glowinski; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1966-02       Impact factor: 4.030

  10 in total
  24 in total

1.  Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.

Authors:  D L Murphy; S Lipper; S Slater; D Shiling
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

2.  Chronic effects of clomipramine and clorgyline on regional levels of brain amines and acid metabolites in rats.

Authors:  D D Mousseau; A J Greenshaw
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

3.  Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.

Authors:  J R Fozard; M G Palfreyman; M Robin; M Zreika
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

4.  Monoamine oxidase in rat arteries: evidence for different forms and selective localization.

Authors:  J F Coquil; C Goridis; G Mack; N H Neff
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

5.  Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition data.

Authors:  C J Fowler; M Strolin Benedetti; V Rovei
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

6.  Selective inhibition by amezinium of intraneuronal monoamine oxidase.

Authors:  A Steppeler; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-10       Impact factor: 3.000

7.  Monoamine oxidase of types A and B in the saphenous vein and mesenteric artery of the dog.

Authors:  M M Caramona
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-05       Impact factor: 3.000

8.  Predominance of oxidative deamination in the metabolism of exogenous noradrenaline by the normal and chemically denervated human uterine artery.

Authors:  D Branco; M Caramona; F Martel; J A de Almeida; W Osswald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

9.  Monoamine oxidase (MAO) activity as a determinant in human neurophysiology.

Authors:  J E Pintar; X O Breakefield
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

10.  The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222.

Authors:  M Strolin Benedetti; T Boucher; C J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.